Filtered By:
Source: Der Ophthalmologe
Nutrition: Vitamin A
This page shows you your search results in order of date.
Order by Relevance | Date
Total 10 results found since Jan 2013.
Update on intravenous lysis treatment : The REVISION trial
CONCLUSION: The efficacy of intravenous thrombolysis in acute ischemic stroke is critically time dependent. This may also be assumed in acute CRAO; however, definite evidence still needs to be provided. Until then, the motto "time is retina" should be applied and intravenous thrombolysis should be offered to CRAO patients as part of randomized trials (such as REVISION). According to the current literature, other acute treatment approaches (such as paracentesis) are not indicated.PMID:34351478 | DOI:10.1007/s00347-021-01467-5
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Maximilian Schultheiss Martin S Spitzer Lars-Olof Hattenbach Sven Poli Source Type: research
Nonaretritic central retinal artery occlusion as marker for the generalized vascular risk
CONCLUSION: Although cardiovascular diseases are already known in most patients at the onset of an RAO, further risk factors are detected in almost 80% of cases. Therefore, and because of the high risk for recurrent thromboembolism, immediate and standardized neurological internal medical clarification of the cause is urgently recommended after an acute RAO in the context of an inpatient stay.PMID:34350493 | DOI:10.1007/s00347-021-01466-6
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Nicolas Feltgen Jan Liman Maximilian Schultheiss Martin S Spitzer Amelie Pielen Sven Poli Source Type: research
Update on intravenous lysis treatment : The REVISION trial
CONCLUSION: The efficacy of intravenous thrombolysis in acute ischemic stroke is critically time dependent. This may also be assumed in acute CRAO; however, definite evidence still needs to be provided. Until then, the motto "time is retina" should be applied and intravenous thrombolysis should be offered to CRAO patients as part of randomized trials (such as REVISION). According to the current literature, other acute treatment approaches (such as paracentesis) are not indicated.PMID:34351478 | DOI:10.1007/s00347-021-01467-5
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Maximilian Schultheiss Martin S Spitzer Lars-Olof Hattenbach Sven Poli Source Type: research
Nonaretritic central retinal artery occlusion as marker for the generalized vascular risk
CONCLUSION: Although cardiovascular diseases are already known in most patients at the onset of an RAO, further risk factors are detected in almost 80% of cases. Therefore, and because of the high risk for recurrent thromboembolism, immediate and standardized neurological internal medical clarification of the cause is urgently recommended after an acute RAO in the context of an inpatient stay.PMID:34350493 | DOI:10.1007/s00347-021-01466-6
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Nicolas Feltgen Jan Liman Maximilian Schultheiss Martin S Spitzer Amelie Pielen Sven Poli Source Type: research
Update on intravenous lysis treatment : The REVISION trial
CONCLUSION: The efficacy of intravenous thrombolysis in acute ischemic stroke is critically time dependent. This may also be assumed in acute CRAO; however, definite evidence still needs to be provided. Until then, the motto "time is retina" should be applied and intravenous thrombolysis should be offered to CRAO patients as part of randomized trials (such as REVISION). According to the current literature, other acute treatment approaches (such as paracentesis) are not indicated.PMID:34351478 | DOI:10.1007/s00347-021-01467-5
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Maximilian Schultheiss Martin S Spitzer Lars-Olof Hattenbach Sven Poli Source Type: research
Nonaretritic central retinal artery occlusion as marker for the generalized vascular risk
CONCLUSION: Although cardiovascular diseases are already known in most patients at the onset of an RAO, further risk factors are detected in almost 80% of cases. Therefore, and because of the high risk for recurrent thromboembolism, immediate and standardized neurological internal medical clarification of the cause is urgently recommended after an acute RAO in the context of an inpatient stay.PMID:34350493 | DOI:10.1007/s00347-021-01466-6
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Nicolas Feltgen Jan Liman Maximilian Schultheiss Martin S Spitzer Amelie Pielen Sven Poli Source Type: research
Update on intravenous lysis treatment : The REVISION trial
CONCLUSION: The efficacy of intravenous thrombolysis in acute ischemic stroke is critically time dependent. This may also be assumed in acute CRAO; however, definite evidence still needs to be provided. Until then, the motto "time is retina" should be applied and intravenous thrombolysis should be offered to CRAO patients as part of randomized trials (such as REVISION). According to the current literature, other acute treatment approaches (such as paracentesis) are not indicated.PMID:34351478 | DOI:10.1007/s00347-021-01467-5
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Maximilian Schultheiss Martin S Spitzer Lars-Olof Hattenbach Sven Poli Source Type: research
Nonaretritic central retinal artery occlusion as marker for the generalized vascular risk
CONCLUSION: Although cardiovascular diseases are already known in most patients at the onset of an RAO, further risk factors are detected in almost 80% of cases. Therefore, and because of the high risk for recurrent thromboembolism, immediate and standardized neurological internal medical clarification of the cause is urgently recommended after an acute RAO in the context of an inpatient stay.PMID:34350493 | DOI:10.1007/s00347-021-01466-6
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Nicolas Feltgen Jan Liman Maximilian Schultheiss Martin S Spitzer Amelie Pielen Sven Poli Source Type: research
Update on intravenous lysis treatment : The REVISION trial
CONCLUSION: The efficacy of intravenous thrombolysis in acute ischemic stroke is critically time dependent. This may also be assumed in acute CRAO; however, definite evidence still needs to be provided. Until then, the motto "time is retina" should be applied and intravenous thrombolysis should be offered to CRAO patients as part of randomized trials (such as REVISION). According to the current literature, other acute treatment approaches (such as paracentesis) are not indicated.PMID:34351478 | DOI:10.1007/s00347-021-01467-5
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Maximilian Schultheiss Martin S Spitzer Lars-Olof Hattenbach Sven Poli Source Type: research
Nonaretritic central retinal artery occlusion as marker for the generalized vascular risk
CONCLUSION: Although cardiovascular diseases are already known in most patients at the onset of an RAO, further risk factors are detected in almost 80% of cases. Therefore, and because of the high risk for recurrent thromboembolism, immediate and standardized neurological internal medical clarification of the cause is urgently recommended after an acute RAO in the context of an inpatient stay.PMID:34350493 | DOI:10.1007/s00347-021-01466-6
Source: Der Ophthalmologe - August 5, 2021 Category: Opthalmology Authors: Nicolas Feltgen Jan Liman Maximilian Schultheiss Martin S Spitzer Amelie Pielen Sven Poli Source Type: research
